image
Healthcare - Biotechnology - NASDAQ - US
$ 8.25
15.2 %
$ 30.4 M
Market Cap
-0.44
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TPST stock under the worst case scenario is HIDDEN Compared to the current market price of 8.25 USD, Tempest Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TPST stock under the base case scenario is HIDDEN Compared to the current market price of 8.25 USD, Tempest Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TPST stock under the best case scenario is HIDDEN Compared to the current market price of 8.25 USD, Tempest Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TPST

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-42 M OPERATING INCOME
-44.14%
-41.8 M NET INCOME
-41.88%
-33 M OPERATING CASH FLOW
-20.73%
-435 K INVESTING CASH FLOW
-155.88%
24.5 M FINANCING CASH FLOW
-31.18%
0 REVENUE
0.00%
-10.9 M OPERATING INCOME
21.43%
-10.9 M NET INCOME
21.38%
0 OPERATING CASH FLOW
100.00%
0 INVESTING CASH FLOW
100.00%
-721 K FINANCING CASH FLOW
-4.02%
Balance Sheet Tempest Therapeutics, Inc.
image
Current Assets 31.5 M
Cash & Short-Term Investments 30.3 M
Receivables 0
Other Current Assets 1.21 M
Non-Current Assets 10 M
Long-Term Investments 0
PP&E 9.53 M
Other Non-Current Assets 485 K
72.96 %2.91 %22.97 %Total Assets$41.5m
Current Liabilities 14.2 M
Accounts Payable 2.45 M
Short-Term Debt 8.09 M
Other Current Liabilities 3.68 M
Non-Current Liabilities 8.14 M
Long-Term Debt 8.14 M
Other Non-Current Liabilities 0
10.96 %36.19 %16.45 %36.41 %Total Liabilities$22.4m
EFFICIENCY
Earnings Waterfall Tempest Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 42 M
Operating Income -42 M
Other Expenses -183 K
Net Income -41.8 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)000(42m)(42m)183k(42m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-218.78% ROE
-218.78%
-100.86% ROA
-100.86%
-118.85% ROIC
-118.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tempest Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -41.8 M
Depreciation & Amortization 389 K
Capital Expenditures -435 K
Stock-Based Compensation 5.3 M
Change in Working Capital 1.61 M
Others 1.52 M
Free Cash Flow -33.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tempest Therapeutics, Inc.
image
TPST has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Tempest Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
967 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
100 K USD 3
9-12 MONTHS
7. News
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data. zacks.com - 1 week ago
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to standard of care alone BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC). globenewswire.com - 1 week ago
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update BRISBANE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 and provided a corporate update. globenewswire.com - 1 month ago
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation of new data supporting the immune component of amezalpat's purported dual mechanism of action that reinforces its potential as a novel cancer treatment at the 2025 American Association for Cancer Research (AACR) Annual Meeting. globenewswire.com - 1 month ago
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP). globenewswire.com - 1 month ago
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in after-hours trading. zacks.com - 2 months ago
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisition, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company has retained MTS Health Partners, L.P., an internationally recognized financial advisor with substantial experience in the biotechnology industry, to support it with the strategic evaluation process. globenewswire.com - 2 months ago
Tempest Reports Year End 2024 Financial Results and Provides Business Update • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial • Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP) globenewswire.com - 2 months ago
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment globenewswire.com - 2 months ago
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis (FAP). globenewswire.com - 3 months ago
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC). globenewswire.com - 4 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 45,000 shares of its common stock under the Company's 2023 Inducement Plan. globenewswire.com - 4 months ago
8. Profile Summary

Tempest Therapeutics, Inc. TPST

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 30.4 M
Dividend Yield 0.00%
Description Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Contact 7000 Shoreline Court, Brisbane, CA, 94080 https://www.tempesttx.com
IPO Date Nov. 12, 2012
Employees 24
Officers Dr. Samuel Whiting M.D., Ph.D. Executive Vice President, Chief Medical Officer and Head of R&D Mr. Justin Trojanowski CPA Corporate Controller, Treasurer & Principal Accounting Officer Ms. Lindsay Young Head of Human Resources Mr. Stephen R. Brady J.D., LLM Chief Executive Officer, President & Director Mr. Nicholas Maestas Chief Financial Officer, Head of Corporate Strategy & Secretary